Shenzhen Weiguang Biological Products Co Ltd Cash Flow Conversion Efficiency
Shenzhen Weiguang Biological Products Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Shenzhen Weiguang Biological Products Co Ltd (002880) has a cash flow conversion efficiency ratio of 0.022x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥51.60 Million ≈ $7.55 Million USD) by net assets (CN¥2.36 Billion ≈ $344.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Shenzhen Weiguang Biological Products Co Ltd (2012–2025)
Cash flow conversion efficiency of Shenzhen Weiguang Biological Products Co Ltd from 2012 to 2025. This chart illustrates how Shenzhen Weiguang Biological Products Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Shenzhen Weiguang Biological Products Co stock price for real-time trading data and today's change.
Shenzhen Weiguang Biological Products Co Ltd Cash Flow Conversion Ratio Explained
Shenzhen Weiguang Biological Products Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Shenzhen Weiguang Biological Products Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenzhen Weiguang Biological Products Co Ltd ranked by their cash flow conversion efficiency. Also see Shenzhen Weiguang Biological Products Co market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shore Bancshares Inc
NASDAQ:SHBI
|
0.072x |
|
ChongQing Zhengchuan Pharmaceutical Packaging Co Ltd
SHG:603976
|
0.038x |
|
SHENWAN HONGYUAN GR.H YC1
F:2X2A
|
0.062x |
|
Global Infotech Co Ltd
SHE:300465
|
0.347x |
|
Guangdong Champion Asia Electronics Co Ltd
SHG:603386
|
0.061x |
|
Acrel Co LTD
SHE:300286
|
0.022x |
|
Formosan Union Chemical Corp
TW:1709
|
0.039x |
|
Citic Guoan Wine Co Ltd
SHG:600084
|
0.005x |
Annual Cash Flow Conversion Efficiency for Shenzhen Weiguang Biological Products Co Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of Shenzhen Weiguang Biological Products Co Ltd from 2012 to 2025. Review Shenzhen Weiguang Biological Products Co free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.45 Billion ≈ $357.80 Million |
CN¥263.18 Million ≈ $38.51 Million |
0.108x | +35.89% |
| 2024-12-31 | CN¥2.24 Billion ≈ $328.40 Million |
CN¥177.77 Million ≈ $26.01 Million |
0.079x | -59.28% |
| 2023-12-31 | CN¥2.05 Billion ≈ $299.34 Million |
CN¥397.94 Million ≈ $58.23 Million |
0.195x | +30198.49% |
| 2022-12-31 | CN¥1.87 Billion ≈ $273.28 Million |
CN¥1.20 Million ≈ $175.46K |
0.001x | -99.53% |
| 2021-12-31 | CN¥1.79 Billion ≈ $261.68 Million |
CN¥246.89 Million ≈ $36.13 Million |
0.138x | -26.25% |
| 2020-12-31 | CN¥1.62 Billion ≈ $237.61 Million |
CN¥303.96 Million ≈ $44.48 Million |
0.187x | +46.04% |
| 2019-12-31 | CN¥1.45 Billion ≈ $212.00 Million |
CN¥185.70 Million ≈ $27.17 Million |
0.128x | +68.15% |
| 2018-12-31 | CN¥1.31 Billion ≈ $191.08 Million |
CN¥99.54 Million ≈ $14.57 Million |
0.076x | +220.52% |
| 2017-12-31 | CN¥1.20 Billion ≈ $176.06 Million |
CN¥28.61 Million ≈ $4.19 Million |
0.024x | -90.47% |
| 2016-12-31 | CN¥506.44 Million ≈ $74.11 Million |
CN¥126.41 Million ≈ $18.50 Million |
0.250x | -34.53% |
| 2015-12-31 | CN¥393.71 Million ≈ $57.61 Million |
CN¥150.09 Million ≈ $21.96 Million |
0.381x | -12.24% |
| 2014-12-31 | CN¥308.86 Million ≈ $45.20 Million |
CN¥134.17 Million ≈ $19.63 Million |
0.434x | +364.69% |
| 2013-12-31 | CN¥223.88 Million ≈ $32.76 Million |
CN¥20.93 Million ≈ $3.06 Million |
0.093x | -89.11% |
| 2012-12-31 | CN¥135.00 Million ≈ $19.76 Million |
CN¥115.88 Million ≈ $16.96 Million |
0.858x | -- |
About Shenzhen Weiguang Biological Products Co Ltd
Shenzhen Weiguang Biological Products Co., Ltd. engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous injection fre… Read more